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I. INTRODUCTION
Appellants consisting of The University of California, the
University of Vienna, and Emmanuelle Charpentier, ( collectively
“UC”), appealed a decision of the Patent Trial and Appeal Board
who unanimously held there was no interference-in-fact between
UC’s application for CRISPR patents, and the CRISPR patents
originally awarded to appellees Broad Institute, Inc., Massachusetts
Institute of Technology, and the President and Fellows of Harvard
College, (collectively “Broad”). 1 The patents disputed involved
CRISPR-Cas9 technology that enables swift cutting of DNA
molecules.2 The CRISPR-Cas9 system has two molecules that
implement a mutation into the DNA, including an enzyme named
Cas9 that cuts twos stands of DNA at a particular location within
the genome, allowing DNA bits to be added or removed.3 The other
molecule is a piece of RNA known as guide RNA (gRNA), which
helps guide the Cas9 enzyme in cutting the right point within the
genome.4 The patents that Broad was awarded were confined to the
use of eukaryotic cells, which is vital in that CRISPR-Cas9 systems
have not been found to naturally exist in eukaryotes5, such as plant
Ali Albazzaz is a 2021 DePaul University College of Law J.D. Candidate. Ali
graduated from the University of Illinois at Chicago (UIC) in 2017, where he
majored in Biological Sciences. At UIC, Ali enjoyed learning the wonders of the
scientific realm and its underlying complexities. Ali decided to attend law school
in order to intertwine his passion for science and law, as he plans to pursue a
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1 Regents of Univ. of California v. Broad Inst., Inc., 903 F.3d 1286, 1289 (Fed.
Cir. 2018).
2 Id.
3 What is CRISPR-Cas9?, YOUR GENOME (Dec. 19, 2016),
https://www.yourgenome.org/facts/what-is-crispr-cas9.
4 Id.
5 Eukaryotic Cell, BIOLOGY DICTIONARY,
https://biologydictionary.net/eukaryotic-cell/ (last visited Oct. 27, 2019).
Eukaryotic cells have a nucleus and organelles, and are enclosed by a plasma
membrane. Organisms that consist of eukaryotic cells include protozoa, fungi,
*
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and animal cells.6 In contrast, UC’s original publication involved
CRISPR-Cas9 systems within the prokaryotic cell setting (single
cell organisms lacking distinct nuclei). 7 As genetic editing in the
form of CRISPR-Cas9 technology enters the realm of eukaryotic
alteration, the instant case demonstrates how patent jurisprudence
can serve as an effective catalyst for the progression toward
idealistic human health.
II. BACKGROUND
A. Factual Background
In August 2012, researchers from UC published an article in
reference to usage of CRISPR-Cas9 and its ability to be used in vitro
in a non-cellular experimental environment. 8 The UC publication
did not report any results of experimentation utilizing CRISPRCas9 within a eukaryotic cell. 9 In February 2013, researchers from
the Broad Institute published an article on their triumphant use of
CRISPR-Cas9 in a human cell line. 10 UC and Broad then both
pursued patent protection for their scientific findings.11
B. Procedural Posture
The Patent and Trial Appeal Board instituted an interference
(an administrative proceeding to determine priority of invention and
patentability of invention); however, Broad moved to terminate
such interference, as they alleged that their successful findings of
CRISPR-Cas9 usage in eukaryotic cells was patentably distinct
from UC’s patent claim of CRISPR-Cas9 usage in prokaryotic
cells.12 Broad’s reasoning for such termination, was based on a
plants and animals. Eukaryotic cells are larger and more complex than
prokaryotic cells, which are found in Archaea and Bacteria, the other two
domains of life.
6 Regents of Univ. of California, 903 F.3d at 1289.
7 Regents of Univ. of California, 903 F.3d at 1286.
8 Regents of Univ. of California, 903 F.3d at 1289 (citing J.A. at 4799–804).
9 Id.
10 Regents of Univ. of California, 903 F.3d at 1289 (citing J.A. at 4682–86).
11 Id.
12 Id. at 1290.
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person of ordinary skill in the art not having a reasonable
expectation that the CRISPR-Cas9 system would work successfully
within the confines of a eukaryotic cell. 13 In taking such reasoning
into account, the Board held no such interference-in-fact, as the
realm of eukaryotic and prokaryotic systems served as non-similar
entities to one another.14 Therefore, a person of ordinary skill in the
art would not have had a reasonable expectation of success in
applying the CRISPR-Cas9 system in eukaryotic cells.15
As such, the Board determined that UC’s claims regarding
CRISPR-Cas9 usage did not render obvious Broad’s claims to its
successful use in eukaryotic cells. 16 Because the respective patents
were filed in the era of the Pre-America Invents Act (Pre-AIA), the
US Court of Appeals for the Federal Circuit had jurisdiction to
resolve the interference issue between the respective parties under
28 U.S.C. § 1295 (a)(4)(a).17
Ultimately, the Federal Circuit Judge favored Broad in
determining there was a lack of reasonable expectation of success
regarding CRISPR-Cas9’s application into the realm of eukaryotic
cells.18 Thus, finding no interference-in fact, the Court rendered
Broad’s usage of CRISPR-Cas9 in eukaryotic cells patentably
distinct from UC’s usage of CRISPR-Cas9 in prokaryotic cells.19
III. LEGAL ANALYSIS
Before analyzing the issues in the case, the Court mentioned
that the Board utilized a two-way test to determine whether a claim
is patentably distinct.20 The Board specifically inquired whether
“the subject matter of a claim of one party would, if prior art, ha[d]
anticipated or rendered obvious the subject matter of a claim of the
opposing party and vice versa.”21 The Court mentioned that if the
threshold of the two-way test is not adhered to, then no such
Regents of Univ. of California, 903 F.3d at 1290.
Id.
15 Id.
16 Regents of Univ. of California, 903 F.3d at 1290 (citing J.A. at 49).
17 Id.
18 Id. at 1296.
19 Id. at 1286.
20 Id. at 1291.
21 Regents of Univ. of California, 903 F.3d at 1291.
13
14
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interference-in-fact is present.22 When the interference-in-fact
centers on an obviousness inquiry, the standard of review involves
a question of law.23
The Court’s analysis included precedence from Graham v.
John Deere Co., where the Supreme Court laid factors to frame a
proper analysis of obviousness including: (1) the scope and content
of the prior art; (2) the differences between the claims and the prior
art; (3) the level of ordinary skill in the art; and (4) objective
considerations of non-obviousness.24 As such, the obviousness
determination mandates a finding that a person of ordinary skill
within the art, would have been inspired to combine the teachings
in prior art, along with having a reasonable expectation of success
in combining such teachings. 25 An analysis of a reasonable
expectation of success is a question of fact.26 Thus, the Court
analyzed the issue of obviousness de novo, and the factual findings,
including the reasonable expectation of success, under a substantial
evidence standard.27
Thus, with the standards of review in-place, the Court is to
analyze the issues of whether the Board: (1) incorrectly included a
rigid test of obviousness that mandated the prior art to include
specific instructions, and (2) whether the Board erred in dismissing
evidence of simultaneous invention as irrelevant.28

Id.
Regents of Univ. of California, 903 F.3d at 1291 (citing WBIP, LLC v. Kohler
Co., 829 F.3d 1317, 1326 (Fed. Cir. 2016)).
24 Regents of Univ. of California., 903 F.3d at 1291 (citing Graham v. John
Deere Co., 383 U.S. 1, 17–18, 86 S. Ct. 684, 15 L.Ed.2d 545 (1966); Arctic Cat
Inc. v. Bombardier Recreational Prods. Inc., 876 F.3d 1350, 1358 (Fed. Cir.
2017)).
25 Regents of Univ. of California, 903 F.3d at 1291 (citing In re Stepan Co.,
868 F.3d 1342, 1345–46 (Fed. Cir. 2017)).
26 Regents of Univ. of California, 903 F.3d at 1291 (citing In re Stepan Co.,
868 F.3d at 1346).
27 Regents of Univ. of California, 903 F.3d at 1291 (citing In re Mouttet,
686 F.3d 1322, 1330–31 (Fed. Cir. 2012)).
28 Regents of Univ. of California, 903 F.3d at 1291.
22
23
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A. Reasonable Expectation of Success
The Court referred to Broad’s expert testimonial from Dr.
Paul Simons.29 Dr. Simons mentioned discrepancies between
prokaryotic and eukaryotic cellular conditions that would make the
functionality of CRISPR-Cas9 in eukaryotes unpredictable. 30 The
unpredictability of such functionality comprised of intracellular
temperature, the concentration of various ions, pH, and the presence
of other molecules that may be present in one type of cell, but not
the other.31 Dr. Simons testimonial included additional matters that
would render a skilled artisan to not have a reasonable expectation
of success regarding CRISPR-Cas9’s application in a eukaryotic
cell.32 The structural differences between the two cell-lines
included, eukaryotic cells having ribonucleases that are absent in
prokaryotic cells.33 Notably, ribonucleases specialize in cutting up
RNA molecules.34 RNA molecules haves an abundance of
functions, from “translating genetic information to regulating the
activity of genes during development, cellular differentiation, and
changing environments.”35
To further the differences between the two-cell lines, Dr.
Simons also mentioned that eukaryotic cells degrade doublestranded RNA, and prokaryotic cells do not. 36 What was concerning
to Dr. Simon, was that the human genome is bigger than an average
bacterial genome, like a eukaryote.37 In addition, the frequency of
similar DNA sequences that are present in the human genome is
different than what is present within a bacterial genome. 38 Overall,
Dr. Simons determined these differences formulated a conclusion
that a skilled artisan would not have a reasonable expectation of
Id. at 1292.
Regents of Univ. of California, 903 F.3d at 1292 (citing J.A. 5527 at ¶ 6.13).
31 Id.
32 Id.
33 Id.
34 Id.
35Role of RNA in Biology, RNA THERAPEUTICS INSTITUTE,
https://www.umassmed.edu/rti/biology/role-of-rna-in-biology/ (last visited Oct.
27, 2019).
36 Regents of Univ. of California, 903 F.3d at 1292.
37 Id.
38 Id.
29
30
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success in implementing CRISPR-Cas9 within the confines of a
eukaryotic cell.39 The Court mentioned that UC’s expert witness Dr.
Dana Carroll was aware of the same issues that persist when
attempting to implement the CRISPR-Cas9 system within the
eukaryotic biological regime. 40 Because of the uncertain nature in
implementation, the Court stated such substantial evidence
represented the issues that could arise in CRISPR-Cas9’s
application within a eukaryotic cell.41
The Court referred to UC inventors’ acknowledgment of doubts
within CRISPR-Cas9’s successful implementation in eukaryotic
cells.42 There was evidence that UC acknowledged the significance
of Broad’s success in implementing CRISPR-Cas9 in eukaryotic
cells.43 The Court also noted that the Board considered evidence in
reference to other gene editing systems, which were not helpful in
analyzing whether there was a reasonable expectation of success of
applying CRISPR-Cas9 in eukaryotic cells. 44 Thus, the Court
supported the Board’s finding of the unpredictable nature of
CRISPR-Cas9’s application within eukaryotic cells and thus, a lack
of reasonable expectation of success.45
B. Specific Instructions
In determining whether the Board erred in adopting a test
mandating specific instructions in the prior art to establish
obviousness, the court found no such error. 46 The Court focused on
specific instructions and its correlation to a reasonable expectation
of success.47 The Board stated that it “look[ed] to whether or not
there were instructions in the prior art that would be specifically
relevant to CRISPR-Cas9,” along with “whether there [were]
examples in the prior art of the success or failure of similar

Id.
Id.
41 Regents of Univ. of California, 903 F.3d at 1293.
42 Id.
43 Id.
44 Id.
45 Regents of Univ. of California, 903 F.3d at 1294.
46 Id.
47 Id. at 1295.
39
40
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systems.”48 The Court discussed the Board’s acknowledgement that
“[s]pecific instructions that are relevant to the claimed subject
matter or success in similar methods or products have directed
findings of a reasonable expectation of success.” 49 The Court
concurred with the Board’s recognition that the combination of only
generalized instructions along with evidence of failures with similar
subject matter was indicative of a lack of reasonable expectation of
success.50 The Court mentioned the Board’s finding that there were
no specific instructions in the art regarding CRISPR-Cas9, that
would enable one of ordinary skill in the art a reasonable
expectation of success. 51 The Court agreed with the Board’s finding
that “the failure demonstrated with other systems would have
indicated the lack of a reasonable expectation of success.” 52 Thus,
the Court saw no error in the Board’s analysis of the lack of specific
instructions, to go along with prior failures of adopting prokaryotic
systems to eukaryotic cells based on general instructions.53
Indicating, that there was indeed a lack of reasonable expectation of
success.54
C. Relevance of Simultaneous Invention Evidence
The Court referred to the Board’s expressive recognition
that simultaneous inventions are evidence of obviousness when
“considered in light of all the circumstances.” 55 The Court
recognized that simultaneous inventions can impact an obviousness
analysis in a few ways.56 First, simultaneous inventions serve as
evidence of the level of skill within the art. 57 Second, simultaneous

Regents of Univ. of California, 903 F.3d at 1295 (citing J.A. 28–29).
Id.
50 Id.
51 Id.
52 Id.
53 Regents of Univ. of California, 903 F.3d at 1295.
54 Id.
55 Regents of Univ. of California, 903 F.3d at 1295 (citing Lindemann
Maschinenfabrik GMBH v. Am. Hoist & Derrick Co., 730 F.2d 1452, 1460
(Fed. Cir. 1984)).
56 Regents of Univ. of California, 903 F.3d at 1295 (citing Monarch Knitting
Mach. Corp. v. Sulzer Morat GmbH, 139 F.3d 877, 883 (Fed. Cir. 1998)).
57 Regents of Univ. of California, 903 F.3d at 1295.
48
49
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inventions are objective evidence that persons of ordinary skill in
the art understand the issue, along with a solution to that issue. 58
UC’s evidence of simultaneous invention, where six independent
research groups succeeded in implementing CRISPR-Cas9 in
eukaryotic cells within a short period of time after UC’s article
publication, demonstrated compelling evidence that there was a
motivation to combine the prior art in this manner.59 However, this
was not necessarily indicative of an expectation of success prior to
the completion of the experiments. 60 The Court ultimately agreed
with the Board, in that simultaneous invention did not establish a
reasonable expectation of success, due to the context of the art at the
time.61 The context of the art included “characteristics of the science
or technology, its state of advance, the nature of the known choices,
the specificity or generality of the prior art, and the predictability of
results in the area of interest.”62 Thus, the Court supported the
Board’s finding of evidence of simultaneous invention; regarding
(1) the state of the art, (2) the statements of the inventors, (3) failures
involving similar technologies, and (4) the remainder of the record
evidence as relevant to an obviousness determination, but not
indicative of a reasonable expectation of success.63
D. Conclusion
Thus, with the amalgamation of factors brought forth, the
Court affirmed the Board’s judgement of no interference-in-fact.64
The Court found that the Board performed an exhaustive analysis
consisting of: (1) a variety of statements by experts for both parties
and the inventors themselves, to go along with previous triumphs
and disappointments in the field; (2), evidence of simultaneous
invention; and (3), the degree to which the art provided instructions
for applying the CRISPR-Cas9 technology in eukaryotic

Id.
Regents of Univ. of California, 903 F.3d at 1296.
60 Id.
61 Regents of Univ. of California, 903 F.3d at 1296 (citing J.A. 23–25).
62 Id.
63 Id.
64 Id.
58
59
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cells.65 The substantial evidence was indicative that there was not a
reasonable expectation of success, thus, the Board did not err in its
finding that there was no interference-in-fact.66
IV. CRISPR INTO THE FUTURE
Regents serves as an emblem of hope as we embark on a new
decade. The Court’s holding is symbolic of just how patent
jurisprudence can catalyze innovation, while invoking limitless
potential. Regents is a blueprint that scientists can favorably adhere
to as they analytically frame their next genetic editing
breakthroughs. Since the Court held Broad’s patent to be distinct, 67
Broad’s revolutionary finding of a particularized genetic editing
technique within eukaryotic cells, combined with the Court’s
respect for such a finding, is indicative of the Circuit’s admiration
of risk taking amid scientific enlightenment. A third party who
wishes to apply CRISPR-Cas9 in eukaryotic cells will need a license
from Broad to utilize the ground-breaking technology in human
cells and eukaryotic cells alike, however, CRISPR-Cas9 is just one
systematic technology. Importantly, other scientists and third
parties are now free to explore other genetic editing techniques
within the eukaryotic regime that could spring human medical
advancement further, as there is now a foundation that such
techniques in eukaryotic cells will be recognized in the legal world.
As a result of Regents, there is now an incentive to increase
genetic editing technique funds for research and development in the
eukaryotic realm, which could begin an age of expansive medical
advancement that borders the line of science fiction. As technology
inevitably improves in the coming-years, our nation could be a
foundational pillar of genetic advances that can cure and alleviate
the most persistent diseases. Medical conditions that are inherently
genetic, including cancer and hepatitis B, could be at the mercy of
not only CRISPR-Cas9, but future genetic editing techniques yet to
be discovered. Had Regents chosen not to recognize genetic
techniques as patentable within eukaryotic cells, there could have
been dire ramifications in human health development. For one,
Id.
Id.
67 Regents of Univ. of California, 903 F.3d at 1296-97.
65
66
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scientists’ motivation to battle the nuances that relay in the complex
genetic make-up of humans, would be considerably stifled.68 There
would be no inclination to delve into research to combat human
genetic deficiencies, as the Federal Circuit wouldn’t recognize such
techniques as patentably distinct. 69 With the Court’s recognition that
such techniques are patentable, the floodgates of human health
preservation and augmentation is now a reality, as issues of free
riding would be neutralized in the face of patent doctrine.
Regents will undoubtedly be remembered as a case that
united the world of science and law, in which patent jurisprudence
mediated a collective understanding of human genius in the realm
of genetic modification. As 2020 commences, an age of discovery
and wonderment is on the horizon for medical advancement, thanks
to the wise decision to honor assertive and daring brilliance in
Regents.

Invention: United States and Comparative Global Trends, NATIONAL
SCIENCE BOARD,
https://www.nsf.gov/statistics/2018/nsb20181/report/sections/inventionknowledge-transfer-and-innovation/invention-united-states-and-comparativeglobal-trends (last visited Nov. 18, 2019) “Patents serve a different purpose.
Inventors often have economic motivations to keep the details of their
inventions secret. The patenting system provides the legal right for a limited
time to exclude others from making, using, offering for sale, or selling the
invention, in exchange for public disclosure of the technical information in the
granted patent.”
69 David S. Olson, Patent Protection for Genetic Innovation: Monsanto and
Myriad, 12 CATO SUPREME COURT REVIEW 283, 299 (2013)
https://www.cato.org/sites/cato.org/files/serials/files/supreme-courtreview/2013/9/olson.pdf.
“By allowing cDNA to be patented, the Court ensured that some incentives flow
to genetic researchers for their discoveries of important gene-disease
correlations.”
68

https://via.library.depaul.edu/jatip/vol30/iss1/4

10

